02 July 2004
Comparison of intrathecal levobupivacaine with and without fentanyl in combined spinal epidural for labor analgesia
Yvonne Lim, Alex T. Sia, Cecilia E. OcampoMed Sci Monit 2004; 10(7): PI87-91 :: ID: 11713
Abstract
Background:The initiation of epidural infusion immediately after intrathecal (IT) injection to prolong labor analgesia has gained increasing popularity. The effect of additional intrathecal fentanyl on levobupivacaine for labor analgesia has not been fully investigated. We wished to determine if addition of IT fentanyl to IT levobupivacaine in combined spinal epidural (CSE) could prolong obstetric analgesia when epidural infusion is initiated promptly.Material/Methods:In this randomized controlled trial, 40 nulliparous parturients in labor were recruited to receive either IT 2.5 mg levobupivacaine (L) or IT 2.5 mg levobupivacaine + 25 ml/h epidural infusion of 0.125% levobupivacaine and 2 x2 test and Kaplan-Meier technique (using a log-rank test), respectively. Sensory block, motor block, pain scores, and post-block side effects were also evaluated.Results:The percentage of parturients with ‘successful’ blocks, i.e. parturients not requiring further analgesic supplementation, was significantly higher in LF (87.5% vs. 44%, p<0.05). The duration of analgesia was also significantly longer in group LF (mean 530 min ±SE65 vs. 361±66, p<0.05).
Conclusions: The addition of 25 µg intrathecal fentanyl to 2.5 mg levobupivacaine as part of CSE for labor analgesia decreased the incidence of labor breakthrough pain and resulted in a longer duration of labor pain relief. This may decrease the need for supplemental labor pain relief and the anesthetists’ workload in the delivery suite.
Keywords: Analgesia, Epidural - adverse effects, Analgesia, Epidural - methods, Analgesia, Obstetrical - adverse effects, Analgesia, Obstetrical - methods, Bupivacaine - administration & dosage, Bupivacaine - adverse effects, Bupivacaine - analogs & derivatives, Fentanyl - administration & dosage, Fentanyl - adverse effects, Injections, Spinal, Labor Stage, First, Oxytocin - administration & dosage, Pain Measurement - drug effects, Parturition, Patient Satisfaction, Pregnancy, Analgesia, Epidural - methods, Analgesia, Obstetrical - methods, Bupivacaine - analogs & derivatives, Fentanyl - adverse effects, Injections, Spinal, Labor Stage, First, Oxytocin - administration & dosage, Pain Measurement - drug effects, Parturition, Patient Satisfaction, Pregnancy
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952